HK1061857A1 - A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride - Google Patents

A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride

Info

Publication number
HK1061857A1
HK1061857A1 HK04104903A HK04104903A HK1061857A1 HK 1061857 A1 HK1061857 A1 HK 1061857A1 HK 04104903 A HK04104903 A HK 04104903A HK 04104903 A HK04104903 A HK 04104903A HK 1061857 A1 HK1061857 A1 HK 1061857A1
Authority
HK
Hong Kong
Prior art keywords
ethoxyüphenoxy
benzoäbüthiophene
piperidin
methoxyphenyl
hydrochloride
Prior art date
Application number
HK04104903A
Other languages
English (en)
Inventor
Douglas Luke Wayne
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1061857A1 publication Critical patent/HK1061857A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK04104903A 2000-10-20 2004-07-06 A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride HK1061857A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24225200P 2000-10-20 2000-10-20
PCT/US2001/027773 WO2002034741A2 (en) 2000-10-20 2001-10-18 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Publications (1)

Publication Number Publication Date
HK1061857A1 true HK1061857A1 (en) 2004-10-08

Family

ID=22914051

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104903A HK1061857A1 (en) 2000-10-20 2004-07-06 A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride

Country Status (26)

Country Link
US (1) US20040014672A1 (xx)
EP (1) EP1328521A2 (xx)
JP (1) JP2004512333A (xx)
KR (1) KR20030037690A (xx)
CN (1) CN1268624C (xx)
AR (1) AR035355A1 (xx)
AU (1) AU2002214534A1 (xx)
BR (1) BR0114792A (xx)
CA (1) CA2426007A1 (xx)
CZ (1) CZ20031098A3 (xx)
EA (1) EA005116B1 (xx)
EC (1) ECSP034560A (xx)
HK (1) HK1061857A1 (xx)
HR (1) HRP20030296A2 (xx)
HU (1) HUP0301403A3 (xx)
IL (1) IL155487A0 (xx)
MX (1) MXPA03003432A (xx)
MY (1) MY125009A (xx)
NO (1) NO20031753L (xx)
NZ (1) NZ525364A (xx)
PE (1) PE20020588A1 (xx)
PL (1) PL360946A1 (xx)
SK (1) SK4902003A3 (xx)
UA (1) UA76124C2 (xx)
WO (1) WO2002034741A2 (xx)
ZA (1) ZA200303061B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283832B2 (en) * 2003-10-10 2011-04-07 Synthon B.V. Solid-state montelukast
ES2349798T3 (es) * 2004-07-22 2011-01-11 Eli Lilly And Company Hidrato variable cristalino de la sal hemisuccinato de (s)-6-(4-(2-((3-(9h-carbazol-4-iloxi)-2-hidroxipropil)amino)-2-metilpropil)fenoxi)-3-piridinocarboxamida.
US20110251143A1 (en) * 2007-12-19 2011-10-13 Spectrum Pharmaceuticals, Inc. Stable elsamitrucin salt formulations
PL2305238T3 (pl) 2009-09-25 2012-07-31 Iasomai Ab N-acetylo-L-cysteina do leczenia endometriozy
PL236889B1 (pl) * 2017-10-03 2021-02-22 Univ Warszawski Medyczny Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182493B1 (pl) * 1995-02-28 2002-01-31 Lilly Co Eli Nowe pochodne benzotiofenu, nowe związki pośrednie i sposób wytwarzania nowych pochodnych benzotiofenu oraz środek farmaceutyczny
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
EP1204656A2 (en) * 1999-07-29 2002-05-15 Eli Lilly And Company A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy] phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene hydrochloride

Also Published As

Publication number Publication date
IL155487A0 (en) 2003-11-23
HUP0301403A3 (en) 2009-05-28
MXPA03003432A (es) 2003-08-07
HUP0301403A2 (hu) 2003-10-28
WO2002034741A3 (en) 2003-01-03
EA200300491A1 (ru) 2003-08-28
WO2002034741A2 (en) 2002-05-02
JP2004512333A (ja) 2004-04-22
NZ525364A (en) 2005-09-30
KR20030037690A (ko) 2003-05-14
CZ20031098A3 (cs) 2003-08-13
MY125009A (en) 2006-07-31
ECSP034560A (es) 2003-06-25
NO20031753D0 (no) 2003-04-15
AR035355A1 (es) 2004-05-12
EA005116B1 (ru) 2004-10-28
AU2002214534A1 (en) 2002-05-06
NO20031753L (no) 2003-04-15
SK4902003A3 (en) 2003-10-07
CN1268624C (zh) 2006-08-09
EP1328521A2 (en) 2003-07-23
BR0114792A (pt) 2003-08-12
US20040014672A1 (en) 2004-01-22
CA2426007A1 (en) 2002-05-02
ZA200303061B (en) 2004-07-19
PE20020588A1 (es) 2002-07-06
UA76124C2 (en) 2006-07-17
HRP20030296A2 (en) 2003-06-30
CN1469872A (zh) 2004-01-21
PL360946A1 (en) 2004-09-20

Similar Documents

Publication Publication Date Title
IL160721A0 (en) Crystalline forms of valacyclovir hydrochloride
AU1234002A (en) Crystalline forms of venlafaxine hydrochloride
HK1034962A1 (en) A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzo ÄbÜthiophene hydrochloride.
HK1061857A1 (en) A novel crystalline form of 6-hydroxy-3-(4-Ä2-(piperidin-1-yl)ethoxyÜphenoxy)-2-(4-methoxyphenyl)benzoÄBÜthiophene hydrochloride
GB0006958D0 (en) Method of manufacturing a transistor
GB0018641D0 (en) A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[ b]thiophene hydrochloride
EP1185266A4 (en) AMORPHOUS FORM OF FEXOFENADINE CHLORYDRATE
IL154278A0 (en) Tartrate salts of thiazolidinedione derivative
EP1444263A4 (en) METHOD FOR IMPROVING THE STABILITY OF A BONE BINDING IMPLANT
IL154275A0 (en) Tartrate salts of thiazolidinedione derivative
IL154277A0 (en) Tartrate salts of thiazolidinedione derivative
TJ399B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ- phenoxy) -2-(4-methoxyphenyl) benzo ÄBÜ thiophene hydrochloride.
TJ398B (en) A novel crystalline form of 6-hydroxy -3-(4-Ä2-(piperidin-1-yl) ethoxyÜ-phenoxy) -2-(4-methoxyphenyl) benzo ÄbÜ thiophene hydrochloride.
IL154274A0 (en) Tartrate salts of thiazolidinedione derivative
CY2344B1 (en) A novel crystalline form of 6-hydroxy-3-(4-(2-(piperidin-1-yl) ethoxy) phenoxy)-2-(4-methoxyphenyl) benzo (b) thiphene hydrochloride.
AU2002352423A8 (en) Process for the manufacture of pharmaceutically acceptable salts of a compound
AU2002253886A1 (en) Form a of fluoxetine hydrochloride
HK1045948A1 (zh) 奧美拉唑的新結晶形式
SI1305310T1 (sl) Tartratne soli derivata tiazolidindiona
AU2003246603A8 (en) Process for providing a stable crystalline form of salbutamol
TW435312U (en) Improved anti-clipping structure for plastic stem of tool
AU146963S (en) A set of masonry blocks
PL349974A1 (en) Holder for a number of toothbrushes
AU140518S (en) A set of trays
AU155257S (en) A set of 12 pillows

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101018